Showing 5411-5420 of 9401 results for "".
- Mount Sinai Researcher Identifies Single Gene Biomarker to Differentiate Between Atopic Dermatitis and Psoriasishttps://practicaldermatology.com/news/mount-sinai-researcher-identifies-single-gene-biomarker-to-differentiate-between-atopic-dermatitis-and-psoriasis/2460472/Mount Sinai researchers have pinpointed a single gene biomarker, nitride oxide synthase 2 (NOS2) that can distinguish atopic dermatitis (AD) and psoriasis with 100 percent accuracy using adhesive tape strips, a non-invasive alternative to skin biopsy. The study, published in the Jou
- Tremfya is First IL-23 Inhibitor Approved for PsAhttps://practicaldermatology.com/news/tremfya-is-first-il-23-inhibitor-approved-for-psa/2460471/FDA has approved Tremfya® (guselkumab) from Janssen Pharmaceutical Companies of Johnson & Johnson for adult patients with active psoriatic arthritis (PsA). Tremfya is the first interleukin (IL)-23 approved for active PsA. The safety and efficacy of
- Study: Pembrolizumab Provides Long-Term Benefits in Patients With Metastatic Melanomahttps://practicaldermatology.com/news/study-pembrolizumab-provides-long-term-benefits-in-patients-with-metastatic-melanoma/2460470/A new 10-year analysis provides new insights into an important question: whether BRAF V600E/K mutation status or previous BRAF inhibitor (BRAFi) therapy with or without a MEK inhibitor (MEKi) affects response to pembrolizumab (Keytruda). This retrospective analysis of three ra
- ISHRS: New Guidelines for Hair Restoration Surgery During COVID-19 Pandemichttps://practicaldermatology.com/news/ishrs-new-guidelines-for-hair-restoration-surgery-during-covid-19-pandemic-1/2460469/Hair restoration surgeries can proceed safely in the midst of the ongoing COVID-19 pandemic, the International Society of Hair Restoration Surgery (ISHRS) says. The organization has established suggested protocols for resuming hair restoration practices and offers patients guidance in f
- Dr. Marilyn Liang Assumes SPD Presidencyhttps://practicaldermatology.com/news/dr-marilyn-liang-assumes-sdp-presidency/2460468/Marilyn Liang, MD is the new president of the
- Arcutis’ Roflumilast Cream Could Be “Game Changer” for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-roflumilast-cream-could-be-game-changer-for-plaque-psoriasis/2460467/Arcutis Biotherapeutics, Inc.’s Roflumilast cream (ARQ-151) produced significant improvements in patients with plaque psoriasis in as early as two weeks, according to a results from a phase 2b trial published in The New E
- Arcutis Initiates Patient Enrollment in Phase 2b Study in Chronic Hand Eczemahttps://practicaldermatology.com/news/arcutis-initiates-patient-enrollment-in-phase-2b-study-in-chronic-hand-eczema/2460466/Arcutis Biotherapeutics, Inc. initiated enrollment in the Phase 2b portion of the Phase 1/2b study of ARQ-252, a potent and highly selective topical small molecule inhibitor of Janus kinase type 1 (JAK1), in adult patients with chronic hand eczema. Topline data from this trial are expected in the
- High Kissability Marks for Restylane Kysse in New Phase 4 Studyhttps://practicaldermatology.com/news/high-kissability-marks-for-restylane-kysse-in-new-phase-4-study/2460465/In a recent first-of-its-kind phase IV, Kissability study for an injectable hyaluronic acid (HA) lip filler, subject satisfaction as well as partner satisfaction were evaluated following treatment with Restylane Kysse. Many consumers report they often keep their lip treatments a
- Cutera Launches Fraxis PROhttps://practicaldermatology.com/news/cutera-launches-fraxis-pro/2460464/Cutera, Inc. is launching Fraxis PRO progressive dermal remodeling technology. Fraxis PRO combines fractional CO2 for skin resurfacing and radiofrequency microneedling for dermal remodeling in a single device. Fraxis PRO treats: Fine Lines
- Azitra Awarded Patent for Engineered Bacterial Strain Discovery Platformhttps://practicaldermatology.com/news/azitra-awarded-patent-for-engineered-bacterial-strain-discovery-platform/2460463/Azitra, Inc. has been issued a patent for the company’s engineered bacterial strain discovery platform. The United States Patent and Trademark Office (USPTO) has issued US Patent No. 10,702,558, which includes broad composition of matter claims that are central to the the company’s pr